A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Summary

Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. ASP5834 is being studied in people with solid tumors who have certain KRAS gene mutations. Some people with solid tumors of the colon or rectum (colorectal cancer), will be given ASP5834 with panitumumab. Panitumumab is a treatment for colorectal cancer.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Solid Tumor
• Non-Small-Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma
• Colorectal Cancer

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Astellas Pharma Inc

Last updated on ClinicalTrials.gov

October 13, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites